Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trickle Portfolio -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (459)	2/27/2001 11:35:14 AM
From: tuck	Read Replies (1) \| Respond to of 1784

Fellow TrickleMavens, >>WASHINGTON (CBS.MW) -- APBiotech, the biotechnology equipment supply unit jointly-owned by Nycomed Amersham and Pharmacia, set the projected range of its 18.2 million-share initial public offering between $15 to $17 per share on Tuesday. At the mid-point of the offering range, the planned IPO would raise $291.2 million in proceeds. Lead underwriter Morgan Stanley Dean Witter is expected to float the company's shares on Nasdaq under the proposed ticker "APBI" this spring, subject to market conditions. A majority of the proceeds from the transaction will be used to pay down debt of U.K.-based Nycomed. Based in Piscataway, N.J., APBiotech -- formed via the 1997 merger of the life sciences units operated by Nycomed (NYE: news, msgs, alerts) and Pharmacia Corp (PHA: news, msgs, alerts) -- makes biotechnology equipment used for gene and protein research. It reported 2000 sales of $927 million. See related story. Post-IPO, Nycomed and Pharmacia will continue to hold a significant stake in the APBiotech with a combined ownership of 91.3 percent of the company's total outstanding shares. As part of the reorganization, Pharmacia will be allotted 87.2 million shares of Class B stock that voting rights of 1.374 votes per share. APBiotech will have 208.6 million shares outstanding following the IPO, putting its market value at roughly $3.3 billion.<< snip Also starting to look at HBIO. Lotsa products. I've recently read about their lab dialysis stuff. Recent IPO at $8, holding at $9 these days. Any of Trickle's lab rats use their stuff? Input on any trickle company's products always appreciated. Cheers, Tuck